2024
Win Ratio Analyses Using a Modified Hierarchical Composite Outcome: Insights From PARAGLIDE-HF
Shoji S, Cyr D, Hernandez A, Velazquez E, Ward J, Williamson K, Sarwat S, Starling R, Desai A, Zieroth S, Solomon S, Mentz R. Win Ratio Analyses Using a Modified Hierarchical Composite Outcome: Insights From PARAGLIDE-HF. American Heart Journal 2024, 280: 70-78. PMID: 39505123, DOI: 10.1016/j.ahj.2024.10.020.Peer-Reviewed Original ResearchNT-proBNPComposite outcomeRenal outcomesEjection fractionHeart failureN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideNT-proBNP thresholdsNT-proBNP changesClinically significant eventsNatriuretic peptideAssessment of treatment effectsHF hospitalizationCardiovascular deathTreatment effectsTreatment benefitComprehensive assessment of treatment effectsPrimary analysisValsartanHF visitsSecondary analysisPatientsHierarchical outcomesOutcomesOn‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of TRANSFORM‐HF
Kittipibul V, Mentz R, Clare R, Wojdyla D, Anstrom K, Eisenstein E, Ambrosy A, Goyal P, Skopicki H, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Velazquez E, Greene S. On‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of TRANSFORM‐HF. European Journal Of Heart Failure 2024, 26: 1518-1523. PMID: 38745502, PMCID: PMC11269016, DOI: 10.1002/ejhf.3293.Peer-Reviewed Original ResearchOn-treatment analysisFollow-upAll-cause mortalityHeart failureOn-treatmentNo significant differenceNon-adherencePost-hocSignificant differenceTime of hospital dischargePost hoc analysisDiuretic statusPatients on-treatmentTorsemide groupOpen-labelFurosemide groupRandomized patientsTRANSFORM-HFHF hospitalizationRandomized trialsFurosemidePatientsTorsemideHospital outcomesOutcome differences
2023
Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure
Mentz R, Ward J, Hernandez A, Lepage S, Morrow D, Sarwat S, Sharma K, Starling R, Velazquez E, Williamson K, Desai A, Zieroth S, Solomon S, Braunwald E, Investigators P. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. Journal Of The American College Of Cardiology 2023, 82: 1-12. PMID: 37212758, DOI: 10.1016/j.jacc.2023.04.019.Peer-Reviewed Original ResearchConceptsSacubitril/valsartanEjection fractionWHF eventNT-proBNPSymptomatic hypotensionHeart failureAmino-terminal pro-B-type natriuretic peptideTerminal pro-B-type natriuretic peptidePro-B-type natriuretic peptidePlasma NT-proBNP levelsAngiotensin-Neprilysin InhibitionNT-proBNP changesNT-proBNP levelsUrgent HF visitsChronic heart failureHeart failure eventsLarge treatment effectsHF hospitalizationHF visitsCardiovascular deathPrimary endpointRenal functionClinical benefitNatriuretic peptideWeek 4
2022
Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial
Ghazi L, O'Connor K, Yamamoto Y, Fuery M, Sen S, Samsky M, Riello R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial. American Heart Journal 2022, 257: 111-119. PMID: 36493842, DOI: 10.1016/j.ahj.2022.12.002.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyAcute heart failureHeart failurePragmatic trialElectronic health recordsSubstantial health care costsBest practice advisoryReduced ejection fractionUsual care armHealth recordsTime of dischargeEvidence-based careHealth care costsClinical decision support systemAHF patientsCare armEligible patientsHF hospitalizationInpatient initiationCardiovascular deathMedication classesEjection fractionMedical therapyPrimary outcomePractice advisory
2019
CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy 10-Year Follow-Up of the STICH Trial
Howlett JG, Stebbins A, Petrie MC, Jhund PS, Castelvecchio S, Cherniavsky A, Sueta CA, Roy A, Piña IL, Wurm R, Drazner MH, Andersson B, Batlle C, Senni M, Chrzanowski L, Merkely B, Carson P, Desvigne-Nickens PM, Lee KL, Velazquez EJ, Al-Khalidi HR, Investigators S. CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy 10-Year Follow-Up of the STICH Trial. JACC Heart Failure 2019, 7: 878-887. PMID: 31521682, PMCID: PMC7375257, DOI: 10.1016/j.jchf.2019.04.018.Peer-Reviewed Original ResearchConceptsRecurrent event analysisSTICH trialCause hospitalizationCause-specific hospitalizationsNon-CV eventsTotal cardiovascular hospitalizationsCoronary artery bypassVentricular ejection fractionCABG groupCause deathHF hospitalizationArtery bypassCardiovascular causesCardiovascular hospitalizationEjection fractionHeart failureIschemic cardiomyopathyRecurrent hospitalizationsMost hospitalizationsEvent analysisHospitalizationPatientsCABGRecurrent eventsTotalRepresentativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized with Heart Failure
Sayeed S, Fudim M, Xu H, Matsouaka R, Heidenreich P, Yancy C, Fonarow G, Velazquez E, Hernandez A, DeVore A. Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized with Heart Failure. Journal Of Cardiac Failure 2019, 25: s151. DOI: 10.1016/j.cardfail.2019.07.436.Peer-Reviewed Original ResearchAcute decompensated heart failurePIONEER-HF trialSacubitril/valsartanHFrEF patientsCause mortalityEjection fractionEligible cohortHeart failureLeft ventricular ejection fractionGWTG-HF registryHF rehospitalization ratesDecompensated heart failureReduced ejection fractionInitial study populationVentricular ejection fractionClinical trial populationsLong-term outcomesDaily clinical practiceTrial eligibility criteriaGWTG-HFHF hospitalizationHospital initiationPIONEER-HFHF readmissionIndex discharge
2018
Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial
Sharma A, Ambrosy AP, DeVore AD, Margulies KB, McNulty SE, Mentz RJ, Hernandez AF, Felker G, Cooper LB, Lala A, Vader J, Groake JD, Borlaug BA, Velazquez EJ. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. ESC Heart Failure 2018, 5: 1035-1043. PMID: 30120812, PMCID: PMC6300815, DOI: 10.1002/ehf2.12334.Peer-Reviewed Original ResearchConceptsWeight loss agentsHeart failureEjection fractionHF hospitalizationNew York Heart Association functional class IIIGlucagon-like peptide-1 (GLP-1) receptor antagonistHeart Failure Treatment studyWeight lossAcute HF hospitalizationEfficacy of liraglutideRecent HF hospitalizationFunctional class IIILast study visitReduced ejection fractionAdvanced heart failureCardiovascular outcome trialsMedian ejection fractionAnalysis of patientsLiraglutide useMultivariable adjustmentStudy drugObese patientsOutcome trialsMedian agePrimary outcome
2015
Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)
Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O'Connor CM. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). The American Journal Of Cardiology 2015, 117: 404-411. PMID: 26704029, PMCID: PMC4718787, DOI: 10.1016/j.amjcard.2015.10.059.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedCause of DeathDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesFurosemideGlobal HealthHeart FailureHospitalizationHumansMaleMiddle AgedRetrospective StudiesSodium Potassium Chloride Symporter InhibitorsStroke VolumeSulfonamidesSurvival RateTorsemideTreatment OutcomeConceptsHeart failureChoice of diureticAcute heart failureDecompensated heart failureNatriuretic peptide levelsLow ejection fractionComparative effectiveness trialHF hospitalizationBlood pressureEjection fractionUnadjusted analysesAcute studyClinical effectivenessEffectiveness trialPeptide levelsPatientsFurosemideSimilar outcomesInverse probabilityPotential pharmacologicTorsemideDiureticsMortalityTrialsFailure
2011
Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both
Shah AM, Hung CL, Shin SH, Skali H, Verma A, Ghali JK, Køber L, Velazquez EJ, Rouleau JL, McMurray JJ, Pfeffer MA, Solomon SD. Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. American Heart Journal 2011, 162: 685-691. PMID: 21982661, DOI: 10.1016/j.ahj.2011.07.015.Peer-Reviewed Original ResearchConceptsLV mass indexRisk of deathRelative wall thicknessDiabetic patientsEjection fractionMass indexHigh riskBaseline LV mass indexLeft ventricular systolic dysfunctionHigher LV mass indexHeart failure post-myocardial infarctionVALIANT Echo studyAtrial volume indexVentricular systolic dysfunctionAge-adjusted modelsQuantitative echocardiographic analysisPost-myocardial infarctionHF hospitalizationLong-term elevationNondiabetic patientsConcentric remodelingSystolic dysfunctionAtrial enlargementHeart failureClinical outcomes
2010
The inter‐relationship of diabetes and left ventricular systolic function on outcome after high‐risk myocardial infarction
Shah AM, Uno H, Køber L, Velazquez EJ, Maggioni AP, MacDonald MR, Petrie MC, McMurray JJ, Califf RM, Pfeffer MA, Solomon SD. The inter‐relationship of diabetes and left ventricular systolic function on outcome after high‐risk myocardial infarction. European Journal Of Heart Failure 2010, 12: 1229-1237. PMID: 20965879, DOI: 10.1093/eurjhf/hfq179.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionRecurrent myocardial infarctionHF hospitalizationRisk of deathMyocardial infarctionCause mortalityHigh riskSpectrum of LVEFHigh-risk post-MI patientsBaseline left ventricular ejection fractionHigher left ventricular ejection fractionHigh-risk myocardial infarctionAcute Myocardial Infarction trialCox proportional hazards modelPost-MI populationHeart failure hospitalizationMyocardial Infarction trialNon-diabetic patientsVentricular systolic functionVentricular ejection fractionPost-MI patientsAcute myocardial infarctionPotent risk factorProportional hazards modelFailure hospitalization
2008
Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study
Meris A, Amigoni M, Uno H, Thune JJ, Verma A, Køber L, Bourgoun M, McMurray JJ, Velazquez EJ, Maggioni AP, Ghali J, Arnold JM, Zelenkofske S, Pfeffer MA, Solomon SD. Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study. European Heart Journal 2008, 30: 56-65. PMID: 19001474, DOI: 10.1093/eurheartj/ehn499.Peer-Reviewed Original ResearchConceptsHigh-risk myocardial infarctionMyocardial infarctionHeart failureIndependent predictorsLA sizeHF hospitalizationVentricular dysfunctionFirst monthBaseline independent predictorsVALIANT Echo studyLeft ventricular dysfunctionGlomerular filtration rateLeft atrial sizeBody surface areaBaseline LAVICause deathAtrial sizeLA enlargementAtrial remodellingEchocardiography studyLA remodellingLA volumeAdverse outcomesLV massFiltration rateRacial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both
Prisant LM, Thomas KL, Lewis EF, Huang Z, Francis GS, Weaver WD, Pfeffer MA, McMurray JJ, Califf RM, Velazquez EJ. Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both. Journal Of The American College Of Cardiology 2008, 51: 1865-1871. PMID: 18466801, DOI: 10.1016/j.jacc.2007.12.050.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBiomarkersBlack or African AmericanCaptoprilFemaleHeart FailureHospitalizationHumansIncidenceMaleMiddle AgedMyocardial InfarctionRetrospective StudiesRisk FactorsSystoleTetrazolesUnited StatesValineValsartanVentricular Dysfunction, LeftWhite PeopleConceptsLeft ventricular systolic dysfunctionHeart failureAcute myocardial infarctionMyocardial infarctionBaseline characteristicsAfrican AmericansMyocardial Infarction ComplicatedAngiotensin receptor blockersCoronary risk factorsOutcomes of patientsRecurrent myocardial infarctionVentricular systolic dysfunctionSimilar clinical outcomesHF hospitalizationCardiovascular morbidityCause mortalityReceptor blockersSystolic dysfunctionVentricular dysfunctionCardiovascular mortalityWhite patientsClinical outcomesPoor outcomeVALIANT trialSubgroup analysis
2007
Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function
Amigoni M, Meris A, Thune JJ, Mangalat D, Skali H, Bourgoun M, Warnica JW, Barvik S, Arnold JM, Velazquez EJ, Van de Werf F, Ghali J, McMurray JJ, Køber L, Pfeffer MA, Solomon SD. Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. European Heart Journal 2007, 28: 326-333. PMID: 17251259, DOI: 10.1093/eurheartj/ehl464.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiac VolumeDisease ProgressionEchocardiography, Doppler, ColorElectrocardiographyFemaleHeart FailureHumansMaleMiddle AgedMitral Valve InsufficiencyMyocardial InfarctionObserver VariationPrognosisProspective StudiesRandomized Controlled Trials as TopicRisk FactorsVentricular Dysfunction, LeftVentricular RemodelingConceptsProgression of MRBaseline mitral regurgitationHeart failureMitral regurgitationAcute myocardial infarctionMyocardial infarctionVentricular sizeMR severityHigh-risk myocardial infarctionModerate-severe mitral regurgitationBaseline MR severityWorse LV functionEnd-systolic volumeLarger LV volumesRegurgitant jet areaAtrial area ratioCV mortalityHF hospitalizationCardiovascular outcomesSystolic dysfunctionVentricular dysfunctionEjection fractionIndependent predictorsClinical outcomesLV function